baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

PROQR THERAPEUTICS EO-,04/ NL0010872495 /

2024-05-08 8:02:07 AM	Chg. -0.0150	Volume	Bid9:58:01 PM	Ask9:55:33 PM	High	Low
1.8170EUR	-0.82%	0 Turnover: 0.0000	1.8280Bid Size: 1,149	1.8760Ask Size: 1,120	1.8170	1.8170

GlobeNewswire 2:00 PM ProQR Announces Preclinical Proof of Concept Data for AX-0810 Axiomer™ RNA Editing Program Targeting...

GlobeNewswire 04-23 ProQR Nominates Martin Maier, PhD to Board and Announces Annual Meeting of Shareholders to be Held M...

GlobeNewswire 04-22 ProQR Highlights Upcoming Presentations on Axiomer™ RNA Editing at ASGCT 27th Annual Meeting

GlobeNewswire 04-19 ProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP Portfolio

GlobeNewswire 03-13 ProQR Announces Year End 2023 Operating and Financial Results

GlobeNewswire 02-15 ProQR Announces Japanese Axiomer™ Patent Upheld Following Opposition Against Its Leading IP Estate f...

GlobeNewswire 01-19 ProQR Highlights New Platform Data from Presentation on Axiomer™ RNA Editing Technology at Deaminet ...

GlobeNewswire 01-05 ProQR and Rett Syndrome Research Trust Join Forces with Axiomer™ RNA Editing Collaboration

GlobeNewswire 2023-12-08 ProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen and Ultevursen Oph...

GlobeNewswire 2023-11-07 ProQR Announces Third Quarter 2023 Operating and Financial Results

GlobeNewswire 2023-11-06 ProQR Strengthens Leading Intellectual Property Estate for ADAR-mediated RNA Editing

GlobeNewswire 2023-09-28 ProQR Announces Participation in the Chardan 7th Annual Genetic Medicines Conference

GlobeNewswire 2023-09-27 ProQR Therapeutics Provides Update on Ophthalmic Assets

GlobeNewswire 2023-09-07 ProQR Announces Webcast of Presentation at the Upcoming HC Wainwright 25th Annual Global Investment ...

GlobeNewswire 2022-03-23 ProQR to Participate in the Cantor Virtual Rare Orphan Disease Summit

GlobeNewswire 2022-03-07 ProQR Appoints John Maraganore, PhD, as Strategic Advisor to the Supervisory Board

GlobeNewswire 2022-02-24 ProQR Announces Fourth Quarter and Full Year 2021 Operating and Financial Results

GlobeNewswire 2022-02-11 ProQR Announces Top-Line Results from Phase 2/3 Illuminate Trial of Sepofarsen in CEP290-mediated LC...

GlobeNewswire 2022-02-07 ProQR to Present at Upcoming SVB Leerink Conference

GlobeNewswire 2022-01-04 ProQR Announces Last Patient Has Completed 12 Month Visit in Phase 2/3 Illuminate Trial of Sepofarse...

GlobeNewswire 2021-12-30 ProQR Announces Amendment to Convertible Debt Financing Agreement with Pontifax Ventures and Kreos C...

GlobeNewswire 2021-12-16 ProQR Announces First Patients Dosed in Phase 2/3 Pivotal Trials of QR-421a for USH2A Mediated Retin...

GlobeNewswire 2021-11-18 ProQR Announces Highlights from Analyst Event

GlobeNewswire 2021-11-11 ProQR to Webcast Virtual Analyst Event on November 18

GlobeNewswire 2021-11-08 ProQR Announces Upcoming Investor Conferences in November and December

PROQR THERAPEUTICS EO-,04/ NL0010872495 /

If you wish to receive reply to your feedback, please provide your email address.